Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03440034 · ClinicalTrials.gov registry record · Phase 1

Study of Pioglitazone in Sporadic Inclusion Body Myositis

A Phase 1 study of Nervous System Diseases and Neuromuscular Diseases, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target
1
Study location

NCT03440034 is a Phase 1 study of Nervous System Diseases and Neuromuscular Diseases that has completed, run by Johns Hopkins University. The registered enrollment target is 19 participants, below the 323-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03440034, a Phase 1 study of Nervous System Diseases and Neuromuscular Diseases, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).

Interventions

  • DRUG Pioglitazone

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2018-05-22
Est. Completion 2020-12-31
Phase Phase 1

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT03440034

The ClinicalTrials.gov registry entry for NCT03440034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (94% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 1 intervention - of which Pioglitazone is the first listed.

NCT03440034 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03440034 about?

NCT03440034 is a clinical study titled "Study of Pioglitazone in Sporadic Inclusion Body Myositis". A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).

What is the current status of trial NCT03440034?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-05-22. Estimated completion is 2020-12-31.

What conditions does trial NCT03440034 study?

This clinical trial studies the following conditions: Nervous System Diseases, Neuromuscular Diseases, Inclusion Body Myositis, Myositis, Muscular Diseases.

What interventions are being tested in trial NCT03440034?

The interventions under investigation include: Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT03440034?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03440034 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nervous System Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.